___

• Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol 2002; 47: 165–168.
• Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, Izumi Y, Matsumoto M, Mishima HK. High frequency of open-angle glaucoma in Japanese patients with Alzheimer’s disease. J Neurol Sci 2006; 246: 79–83.
• McKinnon SJ. Glaucoma: ocular Alzheimer’s disease? Front Biosci 2003; 8: s1140–1156.
• Wostyn P, Audenaert K, De Deyn PP. Alzheimer’s disease: cerebral glaucoma? Med Hypotheses 2010; 74: 973–977.
• McGeer PL, McGeer EG. Innate immunity, local inflammation, and degenerative disease. Sci STKE 2002; 2002: re3.
• Nussenblatt RB, Liu B, Wei L, Sen HN. The immunological basis of degenerative diseases of the eye. Int Rev Immunol 2013; 32: 97–112.
• Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M. Age-related macular degeneration (AMD): Alzheimer’s disease in the eye? J Alzheimers Dis 2011; 24: 615–631.
• Pauleikhoff D. Drusen in Bruch’s membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration. Ophthalmologe 1992; 89: 363–386 (in German with English abstract).
• Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004; 22: 453–465.
• Isas JM, Luibl V, Johnson LV, Kayed R, Wetzel R, Glabe CG, Langen R, Chen J. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 2010; 51: 1304–1310.
• Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K et al. Distinct sites of intracellular production for Alzheimer’s disease Aβ 40/42 amyloid peptides. Nature Med 1997; 3: 1016–1020.
• Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 1999; 155: 853–862.
• Esbjorner EK, Chan F, Rees E, Erdelyi M, Luheshi LM, Bertoncini CW, Kaminski CF, Dobson CM, Kaminski Schierle GS. Direct observations of amyloid β self-assembly in live cells provide ınsights into differences in the kinetics of Aβ(1-40) and Aβ(1-42) aggregation. Chem Biol 2014; 732–742.
• Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region- specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 2002; 70: 493–500.
• Perez-Garmendia R, Gevorkian G. Pyroglutamate-modified amyloid beta peptides: emerging targets for Alzheimer’s disease immunotherapy. Curr Neuropharmacol 2013; 11: 491–498.
• Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997; 273: 729–739.
• Serpell LC. Alzheimer’s amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000; 1502: 16–30.
• Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. P Natl Acad Sci USA 2004; 101: 2817–2822.
• Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279: 46363– 46366.
• Sunde M, Blake C. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 1997; 50: 123–159.
• Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 2004; 78: 243–256.
• Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 2006; 116: 378–385.
• Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486–489.
• Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vision 2003; 9: 184–190.
• Jo DH, Kim JH, Kim JH. How to overcome retinal neuropathy: the fight against angiogenesis-related blindness. Arc Pharmacol Res 2010; 33: 1557–1565.
• Wang J, Ohno-Matsui K, Yoshida T, Kojima A, Shimada N, Nakahama K, Safranova O, Iwata N, Saido TC, Mochizuki M et al. Altered function of factor I caused by amyloid β: implication for pathogenesis of age-related macular degeneration from Drusen. J Immunol 2008; 181: 712–720.
• Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 2005; 115: 2793–2800.
• Harman D. Aging: a theory based on free radical and radiation chemistry. J Gernontol 1956; 11: 298–300.
• Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002; 2: 120–123.
• Kosenko EA, Solomadin IN, Tikhonova LA, Reddy VP, Aliev G, Kaminsky YG. Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord Drug Targets 2014; 13: 112–119.
• Yildirim Z, Ucgun NI, Yildirim F. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. Clinics (Sao Paulo) 2011; 66: 743–746.
• Yu DY, Cringle SJ. Retinal degeneration and local oxygen metabolism. Exp Eye Res 2005; 80: 745–751.
• Remsch H, Spraul CW, Lang GK, Lang GE. Changes of retinal capillary blood flow in age-related maculopathy. Graefes Arch Clin Exp Ophthalmol 2000; 238: 960–964.
• Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H et al. Cerebral blood flow in Alzheimer’s disease. Vasc Health Risk Manag 2012; 8: 599–611.
• Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68: 231–240.
• Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev 2013; 2013: 316523.
• Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014; 21: 2208–2217.
• Aliev G, Obrenovich ME, Tabrez S, Jabir NR, Reddy VP, Li Y, Burnstock G, Cacabelos R, Kamal MA. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid Med Cell Longev 2013; 2013: 962984.
• Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, Hatsuta H, Murayama S, Barnham KJ, Irie K et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 2011; 286: 44557–44568.
• Drobek-Slowik M, Karczewicz D, Safranow K. The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD). Postepy Hig Med Dosw (Online) 2007; 61: 28–37.
• Totan Y, Çekiç O, Borazan M, Uz E, Sogut S, Akyol O. Plasma malondialdehyde and nitric oxide levels in age related macular degeneration. Br J Ophthalmol 2001; 85: 1426–1428.
• Imamura Y, Noda S, Hashizume K, Shinoda K, Yamaguchi M, Uchiyama S, Shimizu T, Mizushima Y, Shirasawa T, Tsubota K. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. P Natl Acad Sci USA 2006; 103:11282-11287.
• Shin TM, Isas JM, Hsieh CL, Kayed R, Glabe CG, Langen R, Chen J. Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. Mol Neurodegener 2008; 3: 16.
• Pauleikhoff D, Zuels S, Sheraidah GS, Marshall J, Wessing A, Bird AC. Correlation between biochemical composition and fluorescein binding of deposits in Bruch’s membrane. Ophthalmology 1992; 99: 1548–1553.
• Jansen JH, Hogasen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Path 1993; 143: 1356–1365.
• Dahlback K, Wulf HC, Dahlback B. Vitronectin in mouse skin: immunohistochemical demonstration of its association with cutaneous amyloid. J Invest Dermatol 1993; 100: 166–170.
• Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK et al. Plasma based markers of [11C] PiB-PET brain amyloid burden. PloS One 2012; 7: e44260.
• Akiyama H, Kawamata T, Dedhar S, McGeer PL. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J Neuroimmunol 1991; 32: 19–28.
• Wang L, Clark ME, Crossman DK, Kojima K, Messinger JD, Mobley JA, Curcio CA. Abundant lipid and protein components of drusen. PloS One 2010; 5: e10329.
• Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Int Med 2005; 258: 395–410.
• Loffler T, Flunkert S, Havas D, Santha M, Hutter-Paier B, Steyrer E, Windisch M. Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging 2013; 34: 2379–2388.
• Eisenberg DT, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 2010; 143: 100–111.
• Percy M, Somerville MJ, Hicks M, Garcia A, Colelli T, Wright E, Kitaygorodsky J, Jiang A, Ho V, Parpia A et al. Risk factors for development of dementia in a unique six-year cohort study. I. An exploratory, pilot study of involvement of the E4 allele of apolipoprotein E, mutations of the hemochromatosis-HFE gene, type 2 diabetes, and stroke. J Alzheimers Dis 2014; 38: 907–922.
• Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol 2003; 162: 413–425.
• Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, Toth CA, Sullivan PM, Bowes Rickman C. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. P Natl Acad Sci USA 2005; 102: 11900–11905.
• Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 2005; 19: 55–66.
• Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ et al. Drusen complement components C3a and C5a promote choroidal neovascularization. P Natl Acad Sci USA 2006; 103: 2328–2333.
• Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000; 70: 441–449.
• Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411–431.
• Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001; 73: 887–896.
• Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer’s Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. P Natl Acad Sci USA 2002; 99: 11830–11835.
• Lin JM, Tsai YY, Wan L, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tsai FJ, Tseng SH. Complement factor H variant increases the risk for early age-related macular degeneration. Retina 2008; 28: 1416–1420.
• Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the ‘common’ neurologic disorders? Neurology 2007; 68: 326–337.
• Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
• Chiu CJ, Milton RC, Gensler G, Taylor A. Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am J Clin Nutr 2007; 86: 180–188.
• Moreira PI. High-sugar diets, type 2 diabetes and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care 2013; 16: 440–445.
• Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, Jun G, Baldwin CT, Deangelis MM, Farrer LA. A search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiol Aging 2014; 35: 1510 e1517–1518.
• Keenan TD, Goldacre R, Goldacre MJ. Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 2014; 132: 63–68.
• Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid- beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 2008; 48: 339–345.
• Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. P Natl Acad Sci USA 2011; 108: E279–287.